Study guide
7.2 Pediatric and Neonatal Pharmacotherapy
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
7.2 Pediatric and Neonatal Pharmacotherapy
Key Takeaways Explain This Topic AI
Developmental pharmacokinetics changes rapidly across pediatric age brackets; neonates possess higher total body water (requiring higher mg/kg loading doses of water-soluble drugs) and immature renal/hepatic clearance pathways.
Phase II glucuronidation is severely deficient in neonates, causing life-threatening chloramphenicol toxicity (Gray Baby Syndrome) and impaired bilirubin clearance.
Potentially lethal excipients in neonates and infants include benzyl alcohol (Gasping Syndrome) and propylene glycol (hyperosmolality, lactic acidosis, and renal tubular necrosis).
Key pediatric drug contraindications include ceftriaxone in neonates (kernicterus and calcium precipitation), fluoroquinolones (cartilage toxicity), tetracyclines in children under 8 (enamel hypoplasia/tooth staining), codeine/tramadol under 12 (fatal CYP2D6-mediated respiratory depression), and ASA in viral illness (Reye's syndrome).
Pediatric doses must be calculated based on weight (mg/kg) or body surface area (mg/m2) and should never exceed standard adult maximum single or daily doses.
Last updated: August 2026
Pediatric Developmental Stages and Pharmacokinetics
Pediatric pharmacotherapy requires distinct considerations from adult medicine because infants and children are continually maturing anatomically and physiologically. The World Health Organization (WHO) and Canadian Paediatric Society (CPS) classify pediatric subpopulations as follows:
- Preterm Neonates: Born before 37 weeks 37\text{ weeks} 37 weeks gestational age
- Full-Term Neonates: 0 to 28 days 0\text{ to }28\text{ days} 0 to 28 days of life
- Infants: 1 month to 12 months 1\text{ month to }12\text{ months} 1 month to 12 months
- Children: 1 year to 12 years 1\text{ year to }12\text{ years} 1 year to 12 years
Adolescents: 12 years to 18 years 12\text{ years to }18\text{ years} 12 years to 18 years +-------------------------------------------------------------------------+
- | DEVELOPMENTAL PHARMACOKINETIC (PK) MATURATION MATRIX |
- +-------------------------------------------------------------------------+
- | ABSORPTION: |
- | - Gastric pH > 4-5 at birth (reaches adult levels by age 2) |
- | -> Increased absorption of acid-labile drugs (ampicillin, penicillin)|
- | -> Decreased absorption of weak acids (phenytoin, phenobarbital) |
- | - Thin stratum corneum & high BSA/weight ratio -> dramatic percutaneous|
- | systemic absorption of topical steroids and toxic substances |
- | |
- | DISTRIBUTION: |
- | - Preterm TBW ~80-85%, Term TBW ~75%, Adults ~60% |
- | -> Larger Vd per kg for water-soluble drugs (gentamicin, vancomycin) |
- | -> Requires HIGHER mg/kg initial / loading doses |
- | - Low serum albumin & reduced binding affinity -> higher free drug |
- | - Bilirubin displacement by sulfonamides/ceftriaxone -> KERNICTERUS |
- | |
- | METABOLISM: |
- | - Severe UGT (glucuronidation) deficiency in neonates -> toxic drug |
- | accumulation (Chloramphenicol -> Gray Baby Syndrome) |
- | - CYP450 ontogeny (CYP3A7 fetal -> CYP3A4 matures over 1-2 years) |
- | - Ages 1-9: Hepatic clearance per kg EXCEEDS adult rates |
- | |
- | EXCRETION: |
- | - GFR & tubular secretion 30-40% of adult at birth (matures by 6-12 mo)|
- | - Prolonged elimination half-life of renally cleared drugs |
- | - Requires EXTENDED dosing intervals (e.g., Gentamicin q24-36h) |
- +-------------------------------------------------------------------------+
- Absorption
Gastric Acid Secretion: Gastric pH is nearly neutral ( pH 6 − 8 \text{pH } 6-8 pH 6 − 8 ) at birth and remains > 4 − 5 > 4-5 > 4 − 5 throughout the first several weeks of life due to immature parietal cell function, reaching adult acidity levels by age 2. This hypochlorhydria increases the oral bioavailability of acid-labile medications (e.g., ampicillin, penicillin G ) while decreasing the bioavailability of weakly acidic medications (e.g., phenobarbital, phenytoin ) that require an acidic stomach for non-ionized dissolution.
Intestinal Motility: Gastric emptying is slow and irregular in neonates and young infants, leading to delayed absorption peaks for many oral medications.
Percutaneous Absorption: Neonates and infants possess a significantly thinner stratum corneum and a remarkably high body surface area to body weight ratio ( B S A / Weight BSA / \text{Weight} BS A / Weight ). Topical medications (e.g., corticosteroids, hexachlorophene, rubbing alcohol, lidocaine ) are absorbed rapidly and extensively into systemic circulation, risking severe systemic toxicity and adrenal axis suppression.
Distribution
Total Body Water (TBW) and Extracellular Fluid (ECF): TBW comprises 80 − 85 % 80-85\% 80 − 85% of body weight in preterm neonates and 75 % 75\% 75% in full-term neonates (compared to 55 − 60 % 55-60\% 55 − 60% in adults). Consequently, hydrophilic drugs (such as aminoglycosides [gentamicin], vancomycin, and beta-lactams ) distribute into a much larger volume of distribution per kilogram. To achieve adequate therapeutic peak serum concentrations ( C max C_{\max} C m a x ), neonates require a higher milligram per kilogram ( mg/kg \text{mg/kg} mg/kg ) loading dose (e.g., gentamicin 4 − 5 mg/kg 4-5\text{ mg/kg} 4 − 5 mg/kg in neonates vs 2 mg/kg 2\text{ mg/kg} 2 mg/kg in adults).
Protein Binding and Bilirubin Displacement: Neonates have lower circulating concentrations of total plasma proteins (albumin and α 1 \alpha_1 α 1 -acid glycoprotein) with reduced binding affinity. Highly protein-bound drugs exhibit higher free active fractions. Critically, drugs that compete for bilirubin binding sites on albumin (e.g., ceftriaxone, sulfamethoxazole/trimethoprim ) displace unconjugated bilirubin, allowing free bilirubin to cross the immature blood-brain barrier and deposit in the basal ganglia, precipitating life-threatening kernicterus (bilirubin encephalopathy) .
Metabolism
Hepatic drug-metabolizing enzymes mature asynchronously (ontogeny). In neonates, Phase I CYP450 enzymes operate at low activity levels (fetal CYP3A7 predominates at birth and is gradually replaced by adult CYP3A4 over the first 1-2 years). Phase II conjugation pathways, particularly uridine diphosphate glucuronosyltransferase (UGT) , are profoundly immature in neonates.
Gray Baby Syndrome: Neonatal inability to glucuronidate chloramphenicol leads to toxic accumulation, mitochondrial respiratory chain inhibition, progressive circulatory collapse, cyanosis, hypothermia, ashen-gray skin pallor, and fatal cardiovascular collapse.
Hypermetabolism in Young Children (Ages 1-9 Years): By age 1 to 2 years, hepatic CYP450 enzyme capacity and hepatic blood flow per kilogram exceed adult levels. Children in this age group frequently clear drugs (e.g., theophylline, carbamazepine, valproic acid, levetiracetam ) faster than adults, requiring larger mg/kg \text{mg/kg} mg/kg daily doses and more frequent dosing intervals.
Excretion
Glomerular filtration rate (GFR) and renal tubular secretion are low at birth (approximately 30 − 40 % 30-40\% 30 − 40% of adult values normalized to BSA in term neonates, and even lower in preterm neonates) due to incomplete nephrogenesis and low renal perfusion pressure. GFR matures rapidly during the first 3 months and reaches adult values by 6 to 12 months of age. Renally eliminated drugs (e.g., gentamicin, vancomycin, ampicillin ) have significantly prolonged elimination half-lives in neonates, requiring extended dosing intervals (e.g., gentamicin administered every 24 to 36 hours 24\text{ to }36\text{ hours} 24 to 36 hours in neonates rather than every 8 hours 8\text{ hours} 8 hours as in older children).
Pediatric Dosing Methodologies and Clinical Calculations
Weight-Based Dosing ( mg/kg \text{mg/kg} mg/kg ): The standard dosing methodology in pediatrics. Doses are specified as mg/kg/dose \text{mg/kg/dose} mg/kg/dose (e.g., acetaminophen 10 − 15 mg/kg/dose 10-15\text{ mg/kg/dose} 10 − 15 mg/kg/dose ) or mg/kg/day \text{mg/kg/day} mg/kg/day divided into multiple doses (e.g., amoxicillin 80 − 90 mg/kg/day 80-90\text{ mg/kg/day} 80 − 90 mg/kg/day divided BID).
Body Surface Area (BSA) Dosing ( mg/m 2 \text{mg/m}^2 mg/m 2 ): Highly accurate method correlating with cardiac output and GFR, standard for antineoplastic agents and narrow therapeutic index drugs. Calculated using the Mosteller Formula : BSA (m 2 ) = Height (cm) × Weight (kg) 3600 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} BSA (m 2 ) = 3600 Height (cm) × Weight (kg)
Maximum Adult Dose Rule: A fundamental pediatric safety principle states that a calculated weight-based pediatric dose must never exceed the maximum recommended adult single or daily dose (e.g., if a 60 kg 60\text{ kg} 60 kg adolescent is prescribed amoxicillin 90 mg/kg/day = 5400 mg/day 90\text{ mg/kg/day} = 5400\text{ mg/day} 90 mg/kg/day = 5400 mg/day , the dose must be capped at the standard adult maximum of 2000 − 3000 mg/day 2000-3000\text{ mg/day} 2000 − 3000 mg/day depending on the clinical indication).
Pediatric Renal Function Estimation: The Cockcroft-Gault equation is not valid in pediatrics. Renal function is estimated using the Updated Bedside Schwartz Equation : eGFR (mL/min / 1.73 m 2 ) = 36.5 × Height (cm) Serum Creatinine ( μ mol/L) \text{eGFR (mL/min}/1.73\text{ m}^2\text{)} = \frac{36.5 \times \text{Height (cm)}}{\text{Serum Creatinine (}\mu\text{mol/L)}} eGFR (mL/min /1.73 m 2 ) = Serum Creatinine ( μ mol/L) 36.5 × Height (cm) (Note: When Serum Creatinine is measured in mg/dL \text{mg/dL} mg/dL , the formula is eGFR = 0.413 × Height (cm) SCr (mg/dL) \text{eGFR} = \frac{0.413 \times \text{Height (cm)}}{\text{SCr (mg/dL)}} eGFR = SCr (mg/dL) 0.413 × Height (cm) .)
- Toxic Excipients and Absolute Drug Contraindications
- Lethal Excipients in Neonates and Infants
Excipient Function & Source Pathophysiology & Toxicity Syndrome
Benzyl Alcohol Antimicrobial preservative in multi-dose injectable vials and flushes "Gasping Syndrome" in neonates: deficient hepatic alcohol dehydrogenase and glycine conjugation cause toxic accumulation of benzoic acid → \rightarrow → severe metabolic acidosis, gasping respirations, seizures, circulatory collapse, death. Use preservative-free normal saline only
Propylene Glycol Solvent in injectable lorazepam, diazepam, phenobarbital, digoxin Deficient hepatic alcohol dehydrogenase in neonates leads to accumulation → \rightarrow → severe hyperosmolality, high anion gap metabolic lactic acidosis, seizures, acute renal tubular necrosis, and intravascular hemolysis
Ethanol Co-solvent in oral liquid formulations CNS depression, hypoglycemia, impaired motor coordination, and potential neurotoxicity in developing brain
Pediatric Drug Contraindications Matrix +-------------------------------------------------------------------------+
- | ABSOLUTE PEDIATRIC DRUG CONTRAINDICATIONS |
- +-------------------------------------------------------------------------+
- | 1. CEFTRIAXONE IN NEONATES (Age < 28 days): |
- | - Displaces bilirubin from albumin -> Kernicterus |
- | - Precipitates with IV Calcium (TPN, Ringer's) -> fatal crystalline |
- | deposits in lungs and kidneys. PREFERRED AGENT: CEFOTAXIME |
- | |
- | 2. CODEINE & TRAMADOL (Age < 12 years; < 18 post-adenotonsillectomy): |
- | - Ultra-rapid CYP2D6 metabolizers convert prodrug to massive toxic |
- | morphine/M1 levels -> fatal respiratory arrest & death |
- | |
- | 3. ACETYLSALICYLIC ACID (ASA) in Viral Illness (Age < 18 years): |
- | - Triggers REYE'S SYNDROME (mitochondrial injury -> acute hepatic |
- | steatosis, severe encephalopathy, hyperammonemia, brain herniation|
- | |
- | 4. TETRACYCLINES (Doxycycline, Minocycline) (Age < 8 years): |
- | - Chelates calcium in growing teeth/bone -> permanent yellow-brown |
- | tooth discoloration, enamel hypoplasia, temporary bone growth halt|
- | |
- | 5. FLUOROQUINOLONES (Ciprofloxacin, Levofloxacin): |
- | - Cartilage toxicity, arthropathy, tendon rupture in growing joints |
- | - Reserved strictly for CF pseudomonal exacerbations or anthrax |
- | |
- | 6. PROMETHAZINE (Age < 2 years): |
- | - Severe, fatal respiratory depression |
- | |
- | 7. VALPROIC ACID (Age < 2 years): |
- | - High risk of fatal mitochondrial hepatotoxicity & microvesicular |
- | steatosis (POLG mutation risk) |
- +-------------------------------------------------------------------------+
- Canadian Paediatric Guidelines for Common Childhood Conditions
- Acute Otitis Media (AOM)
Diagnostic Criteria: Acute onset of signs/symptoms of middle ear inflammation accompanied by middle ear effusion (bulging tympanic membrane).
First-Line Pharmacotherapy (CPS Guidelines): High-Dose Amoxicillin ( 80 − 90 mg/kg/day 80-90\text{ mg/kg/day} 80 − 90 mg/kg/day PO divided BID) for 10 days in children < 2 years < 2\text{ years} < 2 years , or 5 days in children ≥ 2 years \ge 2\text{ years} ≥ 2 years with uncomplicated disease. High doses are required to overcome intermediate penicillin-resistant Streptococcus pneumoniae via altered penicillin-binding proteins (PBPs).
Treatment Failure or Concurrent Purulent Conjunctivitis: Switch to High-Dose Amoxicillin-Clavulanate ( 80 − 90 mg/kg/day 80-90\text{ mg/kg/day} 80 − 90 mg/kg/day amoxicillin component with 6.4 mg/kg/day 6.4\text{ mg/kg/day} 6.4 mg/kg/day clavulanate in a 14 : 1 14:1 14 : 1 or 7 : 1 7:1 7 : 1 ratio to cover beta-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis while minimizing clavulanate-induced diarrhea).
Croup (Laryngotracheobronchitis)
Pathophysiology: Parainfluenza viral infection causing subglottic laryngeal edema and stridor.
Treatment: Single dose of Dexamethasone ( 0.6 mg/kg 0.6\text{ mg/kg} 0.6 mg/kg PO, IM, or IV; maximum 10 − 16 mg 10-16\text{ mg} 10 − 16 mg ) for all severities (mild, moderate, severe) to reduce airway inflammation and hospital admission rates. For moderate-to-severe croup with resting stridor and retractions, administer Nebulized Racemic Epinephrine ( 2.25 % 2.25\% 2.25% , 0.5 mL 0.5\text{ mL} 0.5 mL in 2.5 mL 2.5\text{ mL} 2.5 mL NS) or L -epinephrine L\text{-epinephrine} L -epinephrine ( 1 : 1000 , 5 mL 1:1000, 5\text{ mL} 1 : 1000 , 5 mL ) for rapid microvascular mucosal vasoconstriction, followed by a minimum of 2 to 3 hours of clinical observation for rebound stridor.
Pediatric Analgesia and Antipyresis
Acetaminophen: 10 − 15 mg/kg/dose 10-15\text{ mg/kg/dose} 10 − 15 mg/kg/dose PO every 4 − 6 hours 4-6\text{ hours} 4 − 6 hours (maximum 75 mg/kg/day 75\text{ mg/kg/day} 75 mg/kg/day in infants/children, not to exceed 4000 mg/day 4000\text{ mg/day} 4000 mg/day ). Weight-based dosing must always be used rather than age-based dosing charts.
Ibuprofen: 5 − 10 mg/kg/dose 5-10\text{ mg/kg/dose} 5 − 10 mg/kg/dose PO every 6 − 8 hours 6-8\text{ hours} 6 − 8 hours (maximum 40 mg/kg/day 40\text{ mg/kg/day} 40 mg/kg/day , not to exceed 2400 mg/day 2400\text{ mg/day} 2400 mg/day ). Indicated in infants aged ≥ 6 months \ge 6\text{ months} ≥ 6 months . Avoid in dehydrated children or those with acute renal impairment.